Compare CTBI & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CTBI | RAPP |
|---|---|---|
| Founded | 1903 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1995 | 2024 |
| Metric | CTBI | RAPP |
|---|---|---|
| Price | $70.10 | $27.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $76.67 | $64.21 |
| AVG Volume (30 Days) | 116.4K | ★ 1.3M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | 17.79 | ★ 24.34 |
| EPS | ★ 4.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.55 | $22.06 |
| 52 Week High | $79.92 | $52.93 |
| Indicator | CTBI | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 45.84 |
| Support Level | $67.27 | $25.90 |
| Resistance Level | $72.01 | $31.49 |
| Average True Range (ATR) | 1.64 | 1.94 |
| MACD | 0.15 | 0.63 |
| Stochastic Oscillator | 34.24 | 73.60 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.